research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Use of the drug Wolvit® (biotin 5 mg) in treatment of defuse telogenous alopecia
Wolvit® (biotin 5 mg) is effective and safe for treating hair loss and scalp conditions in women.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research Promising Protocol for In Vivo Experiments with Betulin
A new method improves betulin delivery and shows promise in cancer treatment.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
research Studies on the effect of Betula platyphylla extract on human dermal papilla cell proliferation and its mechanism of action
Betula platyphylla extract, particularly the H3-2 fraction, may help treat hair loss by promoting cell growth and inhibiting a hair loss-related enzyme.
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research Shengfu Oil Enhances the Healing of Full-Thickness Scalded Skin Accompanying the Differential Regulation of β-Catenin, Dlk1, and COX-2
Shengfu oil speeds up wound healing by reducing inflammation and promoting tissue repair.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Alopecia areata
research Alopecia areata
research ERRATUM
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Informacióngratuita Este Trasplante de Cabello
research Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research SnapshotDx Quiz: May 2020
BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
research Reply to “Regarding the risk factors of rituximab‐induced thrombocytopenia in patients with autoimmune bullous diseases”
research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Ritlecitinib may help treat alopecia areata by protecting hair follicles.